Could a common diabetes pill boost lung cancer treatment?
NCT ID NCT05445791
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether adding metformin, a standard diabetes drug, to standard targeted therapy (tyrosine kinase inhibitors) can help people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 312 participants will receive either metformin or a placebo alongside their targeted therapy. The goal is to see if this combination delays resistance to treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Metformin (a diabetes drug) plus a tyrosine kinase inhibitor (targeted cancer pill)
What this could lead to
If it works, this could extend the time that lung cancer stays under control for people with EGFR mutations, delaying disease progression.
What could go wrong
This is a mid-stage trial; earlier studies gave mixed results. Metformin may cause gastrointestinal side effects, and the benefit may be small or absent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Instituto Nacional de Cancerologia
RECRUITINGMexico City, 14080, Mexico
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••